ORLANDO (MedPage Today) -- Most patients receiving off-label rituximab (Rituxan) for secondary progressive multiple sclerosis either improved or showed little further progression, according to results from a small retrospective study. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment